-
Product Insights
NewThymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are...
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
NewNonmelanomatous Skin Cancer – Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...
-
Product Insights
NewThyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in neck and throat, and swollen lymph nodes in the neck. Predisposing factors include female sex, high levels of radiation exposure, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy. The Thyroid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nanrilkefusp Alfa in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nanrilkefusp Alfa in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: SOT-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nanrilkefusp Alfa in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nanrilkefusp Alfa in Metastatic Colorectal Cancer Drug Details: SOT-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nanrilkefusp Alfa in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nanrilkefusp Alfa in Squamous Cell Carcinoma Drug Details: SOT-101 is under development for the treatment of...